{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:00:01Z","timestamp":1791932401776,"version":"4.3.4"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"Supplement_7","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI142785"],"award-info":[{"award-number":["U19AI142785"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UC7AI094660"],"award-info":[{"award-number":["UC7AI094660"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Galveston National Laboratory"},{"DOI":"10.13039\/100007865","name":"University of Texas Medical Branch","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The family Filoviridae consists of several virus members known to cause significant mortality and disease in humans. Among these, Ebola virus (EBOV), Marburg virus (MARV), Sudan virus (SUDV), and Bundibugyo virus (BDBV) are considered the deadliest. The vaccine, Ervebo, was shown to rapidly protect humans against Ebola disease, but is indicated only for EBOV infections with limited cross-protection against other filoviruses. Whether multivalent formulations of similar recombinant vesicular stomatitis virus (rVSV)\u2013based vaccines could likewise confer rapid protection is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here, we tested the ability of an attenuated, quadrivalent panfilovirus VesiculoVax vaccine (rVSV-Filo) to elicit fast-acting protection against MARV, EBOV, SUDV, and BDBV. Groups of cynomolgus monkeys were vaccinated 7 days before exposure to each of the 4 viral pathogens. All subjects (100%) immunized 1 week earlier survived MARV, SUDV, and BDBV challenge; 80% survived EBOV challenge. Survival correlated with lower viral load, higher glycoprotein-specific immunoglobulin G titers, and the expression of B-cell\u2013, cytotoxic cell\u2013, and antigen presentation\u2013associated transcripts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results demonstrate multivalent VesiculoVax vaccines are suitable for filovirus outbreak management. The highly attenuated nature of the rVSV-Filo vaccine may be preferable to the Ervebo \u201cdelta G\u201d platform, which induced adverse events in a subset of recipients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiad157","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T11:22:25Z","timestamp":1683890545000},"page":"S660-S670","source":"Crossref","is-referenced-by-count":28,"title":["A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus"],"prefix":"10.1093","volume":"228","author":[{"given":"Courtney","family":"Woolsey","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch , Galveston, Texas , USA"},{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoriya","family":"Borisevich","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch , Galveston, Texas , USA"},{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystle N","family":"Agans","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch , Galveston, Texas , USA"},{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"O\u2019Toole","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch , Galveston, Texas , USA"},{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla A","family":"Fenton","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch , Galveston, Texas , USA"},{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mack B","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch , Galveston, Texas , USA"},{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek N","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch , Galveston, Texas , USA"},{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"Deer","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch , Galveston, Texas , USA"},{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Gerardi","sequence":"additional","affiliation":[{"name":"Department of Viral Vaccine Development, Auro Vaccines , Pearl River, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nneka","family":"Morrison","sequence":"additional","affiliation":[{"name":"Department of Viral Vaccine Development, Auro Vaccines , Pearl River, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Cross","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch , Galveston, Texas , USA"},{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H","family":"Eldridge","sequence":"additional","affiliation":[{"name":"Department of Viral Vaccine Development, Auro Vaccines , Pearl River, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrius","family":"Matassov","sequence":"additional","affiliation":[{"name":"Department of Viral Vaccine Development, Auro Vaccines , Pearl River, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W","family":"Geisbert","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch , Galveston, Texas , USA"},{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"2024041206141501300_jiad157-B1","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1080\/21645515.2019.1649532","article-title":"Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens","volume":"15","author":"Fathi","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"2024041206141501300_jiad157-B2","author":"Federal Select Agent Program, Centers for Disease Control and Prevention and US Department of Agriculture"},{"key":"2024041206141501300_jiad157-B3","author":"Centers for Disease Control and Prevention"},{"key":"2024041206141501300_jiad157-B4","author":"Centers for Disease Control and Prevention"},{"key":"2024041206141501300_jiad157-B5","author":"Centers for Disease Control and Prevention"},{"key":"2024041206141501300_jiad157-B6","author":"Centers for Disease Control and Prevention"},{"key":"2024041206141501300_jiad157-B7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010805","article-title":"An introduction to the Marburg virus vaccine consortium, MARVAC","volume":"18","author":"Cross","year":"2022","journal-title":"PloS Pathog"},{"key":"2024041206141501300_jiad157-B8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"2024041206141501300_jiad157-B9","author":"World Health Organization"},{"key":"2024041206141501300_jiad157-B10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(19)30614-0","article-title":"Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial","volume":"20","author":"Clarke","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2024041206141501300_jiad157-B11","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01190-17","article-title":"Single-dose trivalent VesiculoVax vaccine protects macaques from lethal Ebolavirus and Marburgvirus challenge","volume":"92","author":"Matassov","year":"2018","journal-title":"J Virol"},{"key":"2024041206141501300_jiad157-B12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI131958","article-title":"Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death","volume":"130","author":"Cross","year":"2020","journal-title":"J Clin Invest"},{"key":"2024041206141501300_jiad157-B13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010433","article-title":"A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge","volume":"16","author":"Woolsey","year":"2022","journal-title":"PloS Negl Trop Dis"},{"key":"2024041206141501300_jiad157-B14","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1128\/JVI.73.5.3723-3732.1999","article-title":"Attenuated vesicular stomatitis viruses as vaccine vectors","volume":"73","author":"Roberts","year":"1999","journal-title":"J Virol"},{"key":"2024041206141501300_jiad157-B15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000212","article-title":"Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda","volume":"4","author":"Towner","year":"2008","journal-title":"PloS Pathog"},{"key":"2024041206141501300_jiad157-B16","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1080\/22221751.2022.2086072","article-title":"Natural history of Sudan ebolavirus infection in rhesus and cynomolgus macaques","volume":"11","author":"Woolsey","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"2024041206141501300_jiad157-B17","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01517-21","article-title":"Bundibugyo ebolavirus survival is associated with early activation of adaptive immunity and reduced myeloid-derived suppressor cell signaling","volume":"12","author":"Woolsey","year":"2021","journal-title":"mBio"},{"key":"2024041206141501300_jiad157-B18","doi-asserted-by":"crossref","first-page":"S436","DOI":"10.1093\/infdis\/jiz613","article-title":"Resistance of cynomolgus monkeys to Nipah and Hendra virus disease is associated with cell-mediated and humoral immunity","volume":"221","author":"Prasad","year":"2020","journal-title":"J Infect Dis"},{"key":"2024041206141501300_jiad157-B19","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2002-3-7-research0034","article-title":"Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes","volume":"3","author":"Vandesompele","year":"2002","journal-title":"Genome Biol"},{"key":"2024041206141501300_jiad157-B20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159090","article-title":"Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease","volume":"7","author":"Cross","year":"2022","journal-title":"JCI Insight"},{"key":"2024041206141501300_jiad157-B21","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1093\/infdis\/jiv284","article-title":"Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection","volume":"212","author":"Geisbert","year":"2015","journal-title":"J Infect Dis"},{"key":"2024041206141501300_jiad157-B22","doi-asserted-by":"crossref","first-page":"S582","DOI":"10.1093\/infdis\/jiy293","article-title":"Postexposure efficacy of recombinant vesicular stomatitis virus vectors against high and low doses of Marburg virus variant Angola in nonhuman primates","volume":"218","author":"Woolsey","year":"2018","journal-title":"J Infect Dis"},{"key":"2024041206141501300_jiad157-B23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrd.2017.251","article-title":"Post-exposure treatments for Ebola and Marburg virus infections","volume":"17","author":"Cross","year":"2018","journal-title":"Nature Reviews Drug Discovery"},{"key":"2024041206141501300_jiad157-B24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.703986","article-title":"Recombinant protein filovirus vaccines protect cynomolgus macaques from Ebola, Sudan, and Marburg viruses","volume":"12","author":"Lehrer","year":"2021","journal-title":"Front Immunol"},{"key":"2024041206141501300_jiad157-B25","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1038\/s41467-020-17446-4","article-title":"Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment","volume":"11","author":"Cross","year":"2020","journal-title":"Nat Commun"},{"key":"2024041206141501300_jiad157-B26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq6364","article-title":"A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates","volume":"14","author":"Hunegnaw","year":"2022","journal-title":"Sci Transl Med"},{"key":"2024041206141501300_jiad157-B27","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1371\/journal.ppat.0030002","article-title":"Effective post-exposure treatment of Ebola infection","volume":"3","author":"Feldmann","year":"2007","journal-title":"PloS Pathog"},{"key":"2024041206141501300_jiad157-B28","first-page":"1377","article-title":"Severe Ebola virus infection complicated by gram-negative septicemia","volume":"372","author":"Kreuels","year":"2015","journal-title":"N Engl J Med"},{"key":"2024041206141501300_jiad157-B29","doi-asserted-by":"crossref","DOI":"10.1128\/mSphereDirect.00325-17","article-title":"Deep sequencing of RNA from blood and oral swab samples reveals the presence of nucleic acid from a number of pathogens in patients with acute Ebola virus disease and is consistent with bacterial translocation across the gut","volume":"2","author":"Carroll","year":"2017","journal-title":"mSphere"},{"key":"2024041206141501300_jiad157-B30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3390\/v10100513","article-title":"Ebola virus causes intestinal tract architectural disruption and bacterial invasion in nonhuman primates","volume":"10","author":"Reisler","year":"2018","journal-title":"Viruses"},{"key":"2024041206141501300_jiad157-B31","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1038\/s41598-020-59976-3","article-title":"Immune correlates of postexposure vaccine protection against Marburg virus","volume":"10","author":"Woolsey","year":"2020","journal-title":"Sci Rep"},{"key":"2024041206141501300_jiad157-B32","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200065119","article-title":"A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease","volume":"119","author":"Foster","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024041206141501300_jiad157-B33","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111094","article-title":"A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever","volume":"40","author":"Cross","year":"2022","journal-title":"Cell Rep"},{"key":"2024041206141501300_jiad157-B34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41541-020-0179-4","article-title":"Rapid dose-dependent natural killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebola virus vaccination","volume":"5","author":"Pejoski","year":"2020","journal-title":"NPJ Vaccines"},{"key":"2024041206141501300_jiad157-B35","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024041206141501300_jiad157-B36","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aab3920","article-title":"EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014\/15 Ebola virus outbreak strain","volume":"349","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"2024041206141501300_jiad157-B37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.774026","article-title":"Single dose of a VSV-based vaccine rapidly protects macaques from Marburg virus disease","volume":"12","author":"Marzi","year":"2021","journal-title":"Front Immunol"},{"key":"2024041206141501300_jiad157-B38","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase \u00bd trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2024041206141501300_jiad157-B39","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad157\/50296865\/jiad157.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/Supplement_7\/S660\/57219312\/jiad157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/Supplement_7\/S660\/57219312\/jiad157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T02:14:43Z","timestamp":1712888083000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/228\/Supplement_7\/S660\/7160880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":39,"journal-issue":{"issue":"Supplement_7","published-online":{"date-parts":[[2023,5,12]]},"published-print":{"date-parts":[[2023,11,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad157","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,15]]},"published":{"date-parts":[[2023,5,12]]}}}